This study is testing a new feature for Medtronic Astra/Azure pacemakers called atrioventricular interval modulation (AVIM) therapy. This therapy aims to help treat high blood pressure (hypertension). You may be able to join if you have high blood pressure and already have, or are planning to get, a dual-chamber pacemaker. Your office systolic blood pressure (the top number) should be between 135 mmHg and 180 mmHg. The study will see if turning on AVIM therapy in the pacemaker can lower your average 24-hour blood pressure after 3 months, and also check for any serious device-related problems. The study plans to enroll 500 people, but its current status is unclear.

Study design

This is a multinational, randomized, double-blind study. Participants will be assigned by chance to either have the AVIM therapy turned ON or OFF in their pacemaker.

What's involved

You will have your blood pressure measured at the start and at 3 months. The study involves a 1-year double-blind phase and a 2-year unblinded phase.

Compensation

Not stated in the trial record.

Follow-up

Your blood pressure will be measured at 3 months after randomization. The study includes a 2-year unblinded phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.